Apples And Oranges? Not All PI3 Kinase Inhibitors Are Created Equal
This article was originally published in Pharmaceutical Approvals Monthly
As development and deal-making activity in the phosphatidyinositol-3-kinase (PI3 kinase) area increases, a crucial question has emerged. Will early investments in pan-selective PI3 kinase inhibitors pay off, or will the more recent focus on isoform-selective compounds prove the better approach to this space?
You may also be interested in...
Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.
$175 million deal nets Roche a novel program of signal transduction inhibitors with utility in cancer and inflammatory disease.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011